Recently, we have described a novel gene, DD3, which is one of the most prostate cancer-specific genes described to date (Bussemakers, M. J. G., van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F. M., Schalken, J. A., Debruyne, F. M. J., Ru, N., and Isaacs, W. B. (1999) Cancer Res. 59, 5975-5979). The prostate cancer-specific expression of DD3 indicates that the DD3 gene promoter is a promising tool for the treatment of prostate cancer. To identify the promoter elements that are responsible for the prostate cancer-specific expression of DD3, we have isolated and characterized the DD3 promoter. Sequence analysis of the DD3 5-flanking region was performed and several promoter-human growth hormone reporter constructs were prepared, which were transiently transfected in the DD3-positive cell line LNCaP and several DD3-negative cell lines. Using a 500-base pair DD3 promoter construct, we could detect promoter activity in LNCaP cells, which was not affected by increasing the size of the constructs. Truncated constructs, however, showed an increased transcriptional activity, suggesting the presence of a silencer that negatively regulates the expression of DD3. DNase-I footprint analysis, using nuclear extracts from LNCaP cells, revealed the presence of three DNase-Iprotected areas within the DD3 proximal promoter. We show that the high mobility group I(Y) protein binds to one of the DNase-I-protected areas and recruits another, yet unidentified, protein to the DD3 promoter in LNCaP cells.Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in the Western male population (1). When this carcinoma has locally or distantly spread, no curative therapy can be offered. Because there is no effective treatment available for patients with advanced and/or hormone-refractory prostate cancer, there is an urgent need to develop new approaches to treat patients with progressive prostate cancer. A better understanding of the molecular changes associated with the onset and progression of prostate cancer may provide a rational basis for the development of new treatment modalities. For example, gene therapy using prostate-specific gene promoters, i.e. linking up prostatespecific promoter sequences to genes that suppress tumor cell growth, induce apoptosis, and/or kill tumor cells, may provide a new way to attack this mordacious disease (2, 3).A number of human genes have been identified that are specifically expressed in the human prostate, including prostate-specific antigen (PSA) 1 (e.g. Ref. (9), and prostate stem cell antigen (10). The promoter sequences responsible for the prostate-specific expression of these genes have been cloned, and the unraveling of their transcriptional regulation is ongoing and will provide prostate-specific promoter fragments that can activate therapeutic agents selectively in prostatic (cancer) cells.The PSA gene promoter has been most extensively studied and revealed the existence of a proximal prostate-specific promoter with an upstr...